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Available online 21 November 2017Objective. ASCCP cervical cancer screening guidelines recommend triaging high-risk human papillomavirus
(hrHPV) positive women with cytology and genotyping, but cytology is often unavailable in resource-limited
areas. We compared the long-term risk of cervical cancer and precancers among type-specific hrHPV-positive
women triaged by viral load to cytology and visual inspection with acetic acid (VIA).
Methods. A cohort of 1742 Chinese womenwas screenedwith cytology, VIA, andHybrid Capture 2 (HC2) test
and followed for ten years. All HC2-positive samples were genotyped. Viral load was measured by HC2 relative
light units/cutoff (RLU/CO). Ten-year cumulative incidence rate (CIR) of cervical intraepithelial neoplasia grade
2 or worse (CIN2+) for type-specific hrHPV viral load was estimated using Kaplan-Meier methods.
Results. Baseline hrHPV viral load stratified by specific genotypeswas positively correlatedwith prevalent cy-
tological lesions. Ten-year CIR of CIN2+ was associated with cytological lesions and viral load. Among HPV 16/
18-positive women, ten-year CIR of CIN2+ was high, even with normal cytology (15.3%), normal VIA (32.4%),
viral load with RLU/CO b 10 (23.6%) or RLU/CO b 100 (33.8%). Among non-16/18 hrHPV positive women, ten-
year CIR of CIN2+ was significantly stratified by cytology grade of atypical squamous cell of undetermined sig-
nificance or higher (2.0% VS. 34.6%), viral load cutoffs at 10 RLU/CO (5.1% VS. 27.2%), at 100 RLU/CO (11.0% VS.
35.5%), but not by VIA (19.1% VS. 19.0%).
Conclusions.Our findings support the guidelines in referring all HPV16/18 positivewomen to colposcopy and
suggest triaging non-16/18 hrHPV positive women using viral loads in resource-limited areas where cytology
screening was inaccessible.
© 2017 Elsevier Inc. All rights reserved.Keywords:
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virus (hrHPV) is a necessary etiology for progression to cervical can-
cer is reinforcing HPV DNA testing incorporated into cervical cancer
screening programs in many countries [1–3]. But potential risk of ex-
cessive colposcopy and overtreatment would occur in women with
transient HPV infections who regressed spontaneously within one
to two years [4,5]. Therefore how to best triage HPV-positive
women through secondary screening to identify those women with
true precancerous lesions remains a pending issue in cervical cancer
screening.
Given the different carcinogenicity of HPV among genotypes, par-
tial typing tests such as HPV 16/18 and HPV 16/18/45 are being inte-
grated into cervical screening to improve the risk stratification of
general population [6–8]. In addition, other triage techniques are
also desirable. The updated guidelines released by American Society
for Colposcopy and Cervical Pathology (ASCCP) recommended the
cytology for triaging the non-16/18 hrHPV positive women [9].
It is no doubt of high specificity of cytology screening [10], neverthe-
less, high-quality cytology screening programs are often unavailable
due to the lacking of trained cytopathologists, limited healthcare
resources, or poor infrastructures in low-resource countries. VIA is
another option for secondary screening of HPV-positive women in
low and middle income settings but with a wide variation of
sensitivity rate from 41% to 92% for CIN2+ detection between
providers [11].
Viral load resulting from productive viral replication might predict
the risk of viral persistence and the progression to high-grade CIN and
cervical cancer [12–16]. The likelihood of the viral load related risk
was reported to be dependent on specific HPV genotypes, as demon-
strated by many large screening population studies from US, Belgium
and Denmark [17–20]. However, few studies focused on the longitudi-
nal comparison of risk stratification of HPV viral load in comparison to
cytology or VIA to date.
Our previously prospective study of a six-year follow-up cervical
cancer screening cohort of 1997 women demonstrated that baseline
high hrHPV viral load was associated with the increased risk of pro-
gression to CIN2+ and potentially served as a biomarker to triage
hrHPV-positive women for colposcopy [21], however, did not specify
the risk of CIN2+ by individual hrHPV type. In this present study,
with the data of a ten-year follow-up of the same cohort, we further
compared the long-term risk stratification of CIN2+ by hrHPV viral
loads against cytology and VIA among HPV 16/18 and non-16/18
hrHPV-positive women, so as to investigate the feasibility of viral
load as an alternative triage method for hrHPV-positive women in
lieu of cytology, especially in regions with high-quality cytology ex-
amination unavailable.
2. Methods
2.1. Study population
A cohort of 1997 women, aged 35–45 years., married, not pregnant,
and without history of hysterectomies, were enrolled in Shanxi Province
of Cervical Cancer Screening I (SPOCCS I) study in 1999 [22]. These partic-
ipants were then followed up through three organized visits in 2005,
2010, and 2014, respectively [23,24]. The incidence and mortality of cer-
vical cancer in this cohortwere also recordedby anational cancer registry.
This study was approved by the Institutional Review Board of Cancer In-
stitute/Hospital, Chinese Academy of Medical Sciences (CICAMS).
2.2. Clinical examinations
Each participantwas screenedwith liquid-based cytology (LBC), Hy-
brid Capture 2 (HC2) testing, visual inspection with acetic acid (VIA) in1999, 2005, 2010, and 2014 (except for VIA in 2014). Women positive
by any of three tests were referred for colposcopy, and lesions visible
under colposcopy were directly biopsied. Cytology results were
interpreted using the Bethesda classification system and histological di-
agnosesweremade according to CIN classifications. Histological diagno-
ses of CIN grade 2, CIN grade 3, squamous cell carcinoma (SCC), and
adenocarcinoma in situ (AIS), or adenocarcinoma were categorized as
CIN2+. Womenwith histology-confirmed CIN2+ lesions were recom-
mended for treatment as per local clinical guidelines.
2.3. HPV DNA testing
HC2 assay was conducted on cervical cytological samples to test the
presence of HPV DNA within two weeks of specimen collection. This
assay detects the DNA of 13 carcinogenic hrHPV types (HPV 16, 18, 31,
33, 35, 39, 45, 51, 52, 56, 58, 59 and 68) but unable to discriminate indi-
vidual genotypes. Samples were deemed as hrHPV-positive if the signal
strength in relative light units compared with standard positive control
(RLU/CO) in HC2 assay was 1.0 (1 pg/mL, approximately 5000 viral
copies) or higher. A semi-quantitative viral load of women positive for
HPV were then categorized into three groups: low (1.0–9.9 RLU/CO),
moderate (10.0–99.9 RLU/CO) and high viral load (≥100.0 RLU/CO),
with the same criteria made by our previous study and other studies
[12,21,25,26].
2.4. HPV genotyping
All HC2-positive cytological specimens were genotyped using PCR-
based reverse hybridization line probe assay (INNO-LiPA Extra,
Innogenetics, Belgium)with a SPF10 primers set (DDL diagnostic labora-
tory, Netherlands) (SPF10-LiPA). This assay identifys 28 hrHPV types on
a line strip, including 13 hrHPV types covered by the HC2 assay, three
probable carcinogenic genotypes (26, 53, and 66), and 12 low-risk ge-
notypes (6, 11, 40, 43, 44, 54, 69, 70, 71, 73, 74, and 82). We defined
hrHPV infections as any positive indication of HPV 16, 18, 31, 33, 35,
39, 45, 51, 52, 56, 58, 59 or 68. Specimens were deemed as hrHPV-neg-
ative if HC2 assay result was negative or if SPF10-LiPA assay result for
these 13 hrHPV genotypes was negative.
2.5. Statistical analysis
A total of 1742 women were examined in 2005 after excluding 255
women due to loss to follow up, hysterectomy, or death during 1999–
2005. Thereafter, 209 hrHPV-positive women in 2005 confirmed by
HPV genotyping were taken as an analytic cohort (AC), as shown in
Fig. 1.
The differences of age were compared among women with low,
medium, or high viral loads using one-way ANOVA method, and
other categorical variables using Pearson Chi-square method.We an-
alyzed the prevalence of cytological lesions in relation to type-spe-
cific HPV viral load. Cumulative incidence rate (CIR) of CIN2+ over
ten-year follow-up by type-specific hrHPV viral loads was estimated
using Kaplan-Meier methods. Hazard ratios were estimated using
Cox proportional hazard models. The CIR of CIN2+ stratified by var-
ious viral load cutoffs, cytology grades, and VIA results among
HPV16/18 positive women and non-16/18 hrHPV positive women
were compared using Log-rank test. All statistical tests were two-
tailed with 0.05 as significance level and all analyses were performed
using SAS 9.2.
3. Results
3.1. Demographic characteristics
Among 209 hrHPV-positive women at AC baseline, the average age
was 45 years and sexual debut age was 21 years. The majority of
Fig. 1. Flowchart of the Shanxi Province Cervical Cancer Screening Study, China, 1999–2014 Abbreviation: HC2=Hybrid Capture 2; LBC= Liquid-based cytology; VIA=Visual inspection
with acetic acid; HPV= Human papillomavirus; CIN2 += Cervical intraepithelial neoplasia grade 2 or worse; AC = Analytic cohort; FU = Follow-up.
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smokers, and premenopausal. Of these women, 4.3% reported their
husband's extramarital sex and 13.7% reported their extramarital sex.
One-third women washed vulvae before or after intercourse. One-
fourth had four or more pregnancies, and one-half gave three full-
term births or more. Except for the number of marriages, no significant
differences for other characteristics amongwomen with different base-
line AC viral load were found (Supplementary Table 1).
3.2. Cervical cytological lesions in relation to baseline genotypes and viral
load
The baseline prevalence of atypical squamous cell of undetermined
significance or higher (ASCUS+) among 209 hrHPV-positive women
was positively correlatedwith baseline hrHPV viral load stratified by ge-
notypes (ptrend b 0.001), as shown in Table 1. The prevalence of ASCUS+
increased with the incremental viral loads ranging from 41.7% to 82.9%
amongHPV16/18 positive women and from 37.2% to 68.6% among non-
16/18 hrHPV positive women. HPV 16 positive women with high viralloads had a significantly higher proportion of high squamous
intraepithelial lesions (HSIL) (55.2%) than those with low (25.0%) or
moderate viral loads (38.7%) (p b 0.05).
3.3. Detection of CIN2+ cases by baseline genotypes and viral load
The number of detected CIN2+ cases depended on both HPV geno-
types and viral load, as shown in Table 2. Themajority (96.5%) of CIN2+
caseswere infectedwith at least one type of HPV 16 (63.2%), 58 (12.3%),
31 (12.3%), 18 (3.5%), 33 (7.0%), 45 (3.5%), or 52 (5.3%). Baseline CIN2+
cases were almost equally distributed among women with moderate
viral load (42.9%) and high viral load (57.1%), by contrast, half of fol-
low-up cases were mainly distributed among women with high viral
load.
3.4. CIR of CIN2+ by HPV genotypes and baseline viral load
High viral load of specific hrHPV type in different viral species at
baseline predicted an incremental ten-year CIR of CIN2+, as illustrated
Table 1
Distribution of abnormal cytology at analytic baseline stratified by type-specific HPV viral load in 209 hrHPV-positive women.
Alpha HPV viral load at analytic baselineb N Cytology results at analytic baseline ptrendd
NILM % ASCUS % LSIL % HSIL %c ASCUS + %
Any hrHPV Low 67 61.2 17.9 9 11.9 38.8 b0.001
Moderate 72 37.5 22.2 9.7 30.6 62.5
High 70 24.3 17.1 24.3 34.3 75.7
HPV 16/18 Low 24 58.3 20.8 0 20.8 41.7 0.001
Moderate 36 25 25 11.1 38.9 75.0
High 35 17.1 17.1 17.1 48.6 82.9
Non-16/18 hrHPV Low 43 62.8 16.3 14.0 7.0 37.2 0.006
Moderate 36 50.0 19.4 8.3 22.2 50.0
High 35 31.4 17.1 31.4 20.1 68.6
HPV16/18/31/33/45/52/58 Low 55 54.5 21.8 9.1 14.5 45.5 0.000
Moderate 64 34.4 21.9 9.4 34.4 65.6
High 59 18.6 16.9 25.4 39.0 81.4
HPV 16 Low 20 50.0 25.0 0 25.0 50.0 0.002
Moderate 31 29 19.4 12.9 38.7 71.0
High 29 10.3 13.8 20.7 55.2 89.7
HPV 18a Low 4 100 0 0 0 0 0.230
Moderate 5 0 60 0 40 100
High 6 50.0 33.3 0 16.7 50.0
HPV 31a Low 5 60.0 20.0 20.0 0 40.0 0.500
Moderate 7 28.6 28.6 0 42.9 71.4
High 8 37.5 12.5 25.0 25.0 62.5
HPV 33a Low 9 55.6 11.1 33.3 0 44.4 0.075
Moderate 7 42.9 28.6 0 28.6 57.1
High 8 12.5 37.5 37.5 12.5 87.5
HPV 52a Low 14 42.9 35.7 7.1 14.3 57.1 0.552
Moderate 13 61.5 15.4 7.7 15.4 38.5
High 4 50 0 25.0 25.0 50.0
HPV 58a Low 7 57.1 14.3 14.3 14.3 42.9 0.082
Moderate 7 14.3 28.6 14.3 42.9 85.7
High 11 18.2 0 45.5 36.4 81.9
Abbreviation: HPV= Human papillomavirus; hrHPV= High-risk human papillomavirus; NILM= Negative for intraepithelial lesion or malignancy; ASCUS = Atypical squamous cell of
undetermined significance; LSIL = Low grade squamous intraepithelial lesion; ASCUS +=Atypical squamous cell of undetermined significance or worse; HSIL = High grade squamous
intraepithelial lesion;
a Women concurrently infected with HPV 16 were not included in the final analysis.
b HPV viral load was categorized by RLU/CO ratio: 1–9.99 RLU/CO as low; 10–99.99 RLU/CO as moderate; ≥100 RLU/CO as high.
c HSIL included four cases of ASCUS-H.
d p trend was calculated using Chi-square methods to compare the proportions of ASCUS+ with increased viral loads from low to high level stratified by hrHPV types.
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stratification of CIN2+ with HR of 4.6 (95% CI: 2.0 to 10.6) was seen
between women with low and high viral load with CIR of 16.2% and
59.2%, respectively. By contrast, no notable stratification was observed
for any alpha-7 species positive women. Significant risk stratification
was also observed when all non-16/18 types were combined (HR =
7.3, 95% CI = 1.6 to 32.8) with CIR of 5.1% versus 35.5%. The trend of
risk stratifications by type-specific hrHPV viral loads was similar even
after CIN2+ cases at baseline were excluded from 209 hrHPV-positive
women to estimate incident CIN2+ (Supplementary Fig. 1).Table 2
Cumulative detection of CIN2+ in 209 hrHPV-positive women, stratified by timing of detectio
HPV infection status at AC baseline AC baseline CIN2+ cases (N= 21) % AC
FU
Overall HPV viral loadsb Ov
Low Moderate High
Any hrHPV 100 0 42.9 57.1 100
HPV 16/18 71.4 0 28.6 42.8 63.
Non-16/18 hrHPV 28.6 0 14.3 14.3 36.
HPV16/18/31/33/45/52/58 95.2 0 42.9 52.4 97.
HPV 16 71.4 0 28.6 42.8 58.
HPV 18a 0 0 0 0 5.6
HPV 31a 9.8 0 4.9 4.9 13.
HPV 33a 4.8 0 0 4.8 8.3
HPV 52a 0 0 0 0 8.3
HPV 58a 19.0 0 9.5 9.5 8.3
Abbreviation: HPV= Human papillomavirus; hrHPV = High-risk HPV; CIN2 +=Cervical intr
a Women concurrently infected with HPV 16 were not included in the final analysis.
b HPV viral load was categorized by RLU/CO ratio: 1-9.99 RLU/CO as low; 10-99.99 RLU/CO3.5. CIR of CIN2+ by triage methods
The CIRs of CIN2+ among HPV 16/18 and non-16/18
hrHPV positive women were statistically stratified by ASCUS+
and viral load cutoffs (Fig. 3). Among HPV 16/18-positive women,
ten-year CIR of CIN2+ was high albeit with normal cytology
(15.3%), normal VIA (32.4%), viral load with RLU/CO b 10 (23.6%) or
RLU/CO b 100 (33.8%). Among non-16/18 hrHPV positive women,
ten-year CIR of CIN2+ was significantly stratified by cytology
grade of ASCUS+ (2.0% VS. 34.6%), viral load cutoffs at 10 RLU/COn, by HPV viral load.
new cases of CIN2+ over 10-year of
(N= 36) %
AC accumulative cases of CIN2+ at
baseline and 10-year of FU (N= 57) %
erall HPV viral loadsb Overall HPV viral loadsb
Low Moderate High Low Moderate High
19.5 30.6 50.0 100 12.3 35.1 52.6
9 13.9 22.2 27.8 66.7 8.8 24.6 33.3
1 5.6 8.3 22.2 33.3 3.5 10.5 19.3
2 19.4 30.6 47.2 96.5 12.3 35.1 49.1
3 13.9 16.7 27.8 63.2 8.8 21.1 33.3
0 5.6 0 3.5 0 3.5 0
9 0 5.6 8.3 12.3 0 5.3 7.0
2.8 0 5.6 7.0 1.8 0 5.3
0 5.6 2.8 5.3 0 3.5 1.8
2.8 0 5.6 12.3 1.8 3.5 7.0
aepithelial neoplasia 2 or worse; AC = Analytic cohort; FU = Follow-up.
as moderate; ≥100 RLU/CO as high.
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(19.1% VS. 19.0%).
4. Discussion
Our study is among the first to assess the optimum triage strategies
of HPV 16/18 positive women and non-16/18 hrHPV positive by type-
specific HPV viral loads, in comparison to cytology grade and VIA in a
population-based cervical cancer screening cohort. We found that
HPV16/18 positive women had a high risk of CIN2+ even with a low
viral load or normal cytology and non-16/18 hrHPV positive women
has a striking risk stratification by cytology and suitable viral load cut-
offs. However, VIA may not be a viable risk triage tool for non-16/18
hrHPV positive women.
We evaluated the association between hrHPV viral load and preva-
lent cytological and histological lesions, and the predictive value of
CIN2+ by hrHPV genotypes. Among 13 hrHPV genotypes, HPV 16
viral load had the strongest dose-dependent effect with cytological le-
sions and CIN2+, which supported existing evidences on the varied
carcinogenicity of type-specific hrHPV [6,27], and was also in line with
other studies that HPV 16 viral load can stratify the prevalent risks of cy-
tological lesions and the risk of CIN and cancers [17,28–30]. Moreover,
consistent with the US ALTS trial [31], we also found that the elevated
risks of CIN2+ for high viral loads appeared to be specific to alpha-9 as-
sociated types, although our study power was rather limited for more
rare HPV type assessments.Fig. 2. Ten-year cumulative incidence rate of cervical intraepithelial neoplasia grade 2 or worse
Abbreviation: AC = Analytic cohort; HPV = Human papillomavirus; hrHPV = High-risk HPV;
worse; HR = Hazard ratio; CI = Confidence interval; non-HPV16 = A group of species 9 o
other than HPV18. Note: ⁎ Women concurrently infected with HPV 16 were not included in
Moderate = 10–99.99 RLU/CO; High = 100 or higher RLU/CO; ‡ Moderate viral load was takeIn regard to HPV 18, the association of viral load with the risk of
high-grade CIN was not consistent among studies [32–34]. Our current
data showed that all of incident CIN 2+ cases among HPV 18 positive
women were infected with moderate viral load, rather than high load,
albeit our limited sample size to evaluate this association. This finding
indicated that HPV 18-induced cervical lesionswasmore likely to be as-
sociated with increased HPV transcript rather than viral copies, [35]
more integrated than episome status in the invasive cancer [36]. Be-
sides, HPV 18, as a representative type of alpha-7 species, was found
to be strongly associated with adenocarcinoma [37–39]. The glandular
epithelium of adenocarcinoma does not support productive HPV infec-
tion, therefore, the low viral load in this type of malignancy results in
the difficulty of HPV detection and the underestimation of the associa-
tion of HPV 18 loads with glandular lesions [40].
Among non-16/18 hrHPV genotypes, special attention should be
given to HPV 31 and HPV 33 due to their high carcinogenicity [6,41],
and to HPV 52 and 58 due to their high prevalence in Asian women
[42]. We noticed that these four genotypes had a substantially higher
risk of CIN2+ over the follow-up than at baseline, indicating that a
long time was needed to progress from infection to high-grade CIN
compared with HPV16, which was consistent with other studies [19].
Although the trends of prevalent cytological lesions in positive relation
to viral load of these genotypes could be seen, the increasing risk of
CIN2+was unable to reach statistical significance. The observed trends
might not be due to random variation, because prevalent cytology le-
sions or prospective risk of CINs in women with the increased highin 209 hrHPV-positive women, stratified by type-specific hrHPV viral loads at AC baseline
CIR = Cumulative incidence rate; CIN2 += Cervical intraepithelial neoplasia grade 2 or
ncogenic types other than HPV16, non-HPV18 = A group of species 7 oncogenic types
the analysis. † HPV viral load was categorized by RLU/CO ratio: Low = 1–9.99 RLU/CO;
n as the reference to evaluate the HR of high viral load. The x-axis is logarithmic.
Fig. 3.Ten-year cumulative incidence rate of cervical intraepithelial neoplasia grade 2 orworse in 209 hrHPV-positivewomen, stratifiedby triagemethods according toHPV16/18 infection
status at AC baseline Abbreviation: HPV=Human papillomavirus; hrHPV=Human-risk HPV; AC=Analytic cohort; CIR= Cumulative incidence rate; CIN2+=Cervical intraepithelial
neoplasia grade 2 orworse; CI= Confidence interval; HR=Hazard ratio; NILM=Negative for intraepithelial lesion ormalignancy; VIA=Visual inspectionwith acetic acid; Note: The x-
axis is logarithmic.
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[31,43]. However, considering different sensitivities among methods
of measuring viral loads [38], further studies involving larger sample
sizes of HPV 31, 33, 52 and 58 positive women and measurement of
viral load by sensitive quantitative methods, such as RT-PCR, are
warranted.
HPV life cycle strictly follows the differentiation program of cellular
DNAmachinery. The viral load reflects the increase of the number of in-
fected cells or viral copies in individual cells. Therefore, the possible
mechanism of high viral load associated with the incremental risk of
cervical neoplasia was an elevated likelihood of having cells with
transforming infections and viral integrating into cellular genome as in-
creasing numbers of infected cells and/or increasing numbers of viral
copies in individual cells [44,45] . Moreover, the duration of persistent
high viral load rather than baseline viral load determined the extent of
this likelihood, as supposed by our previous study and and Gravitt
Patti E.'s study [17,21].
HPV 16/18 positivewomenwere recommended for direct referral to
colposcopy and non-16/18 hrHPV positive women were recommended
for triagingwith cytology to colposcopy according to theupdated guide-
lines [9]. Our data showed that HPV16/18 positive women, even with
normal cytology, normal VIA, or low viral load still suffered from a nota-
bly high risk of CIN2+. This finding supports the ASCCP guidelines in
managing the HPV16/18 positive women to avoid missed diagnosis of
CIN2+ cases that might occur with further triage [9]. On the other
hand, among non-16/18 hrHPV positive women, the CIR of CIN2+
could be stratified by a cytology grade of ASCUS+ and by viral load cut-
offs, but not by VIA. This data suggests that triaging non-16/18 hrHPV-
positive women to colposcopy using a suitable viral load cutoff could
be a feasible option in low-resource areas without cytology screening.
2013 WHO guidelines recommended HPV testing followed by VIA
triage in underserved countries [46]. Therefore, the feasibility of triaging
HPV16/18 positive women and non-16/18 hrHPV-positive women
using VIA was evaluated in our study. Risk stratification by VIA was
only significant among HPV16/18 positive women, but was not obvious
among non-16/18 hrHPV positive women. Therefore, our data does notsupport using VIA as a triaging tool for non-16/18 hrHPV-positive
women. This finding could be explained by a previous finding by
Jeronimo J et that VIA was less sensitive for non-16/18 HPV than for
HPV 16/18, since HPV 16 was most likely to cause robust visual
(aceto-white) changes [47].
This present findings of HPV viral loads as an alternative to cytology
in stratifying the risk of high-grade CIN contributed valuable data for fu-
ture discussions related to the potential application of viral load mea-
surement to increase test specificity in cervical cancer screening. The
well-organized follow-up of the population by both active follow-up
through three organized screenings and passive follow-up through a
nationwide cancer registry in our study ensured minimal missing re-
ports of cervical cancer and precursors cases over ten years. Neverthe-
less, several limitations are also needed to address. Firstly, the age
range of participants at baseline was narrow, which covers the natural
age range of peri-menopause for Chinese women [48]. Therefore, cau-
tions should be taken in applying this study's conclusions to younger
women. Secondly, small sample size of individual rare types-positive
women stratified by viral loads limited our statistical power to drawde-
finitive conclusions regarding disease progression. However, the trends
point to the need for further investigation. Finally, viral load was esti-
mated using RLU/CO in HC2 assay in a semi-quantitativemethod, there-
fore the absolute risk of cervical cytology and histology related with
viral loads may not be directly comparable to other studies. Neverthe-
less, HC2 RLU/CO viral load measurement was found to correlate well
with real-time PCR viral load measurement [25]. Meanwhile, semi-
quantitative crude estimation does not affect the generalizability
about the validity of viral loads in comparison to cytology and VIA that
were derived from the same risk estimation standard.
Because of comparable clinical performance, independence from
provider's experience and lower economic cost compared with cytolo-
gy, HPV viral load testing has the potential application as an alternative
of cytology in future clinical practice, especially in the regions with
cytology inaccessible, although the extent to which these findings can
be transformed into clinical practice must be rigorously verified in
the context of viral load measurement methods and the variation of
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load as a triagemethod, if measured by an assay which could be read si-
multaneously with HPV test, would potentially minimize the financial
dependence for additional sampling and biomarker testing as required
by cytology.
In conclusion, our study showed a potential role of viral load in strat-
ifying the risk for hrHPV positivewomen, provided consistent evidences
with ASCCP guidelines of directly referring HPV 16/18 positive women
to colposcopy, and suggested triaging non-16/18 hrHPV positive
women using viral loads in resource-limited countries. This present
finding from population-baesd cohort data will benefit some countries
with comparable settings with China. Nevertheless, more large scale
population trials from different settings or regions are needed to ensure
the clinical performance before HPV DNA viral load as a triage method
was transformed into clinical practice globally.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ygyno.2017.11.016.
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